Shares of Novo Nordisk ($NVO) are up 3% at the time of writing after the Centers for Medicare & Medicaid Services (CMS) announced price cuts

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month. Then the monthly cost will rise to $349.

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease. Novo Nordisk stock recently stood about 5.

PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.

New research suggests that drugs like Ozempic and Wegovy might trigger more than just a slimmer waistline. Many users have reported digestive issues while taking the medications, including nausea, vomiting, constipation and diarrhea, along with headaches, fatigue and changes to the skin.